CL2023001298A1 - Tecnología de encapsulación de cannabinoides - Google Patents

Tecnología de encapsulación de cannabinoides

Info

Publication number
CL2023001298A1
CL2023001298A1 CL2023001298A CL2023001298A CL2023001298A1 CL 2023001298 A1 CL2023001298 A1 CL 2023001298A1 CL 2023001298 A CL2023001298 A CL 2023001298A CL 2023001298 A CL2023001298 A CL 2023001298A CL 2023001298 A1 CL2023001298 A1 CL 2023001298A1
Authority
CL
Chile
Prior art keywords
cannabinoid
encapsulation technology
permeability enhancer
cannabinoids
encapsulated
Prior art date
Application number
CL2023001298A
Other languages
English (en)
Inventor
Ryu Takechi
John Mamo
Armin Mooranian
Maimuna Majimbi
Emily Brook
Hani Al-Salami
Original Assignee
Zelira Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020904057A external-priority patent/AU2020904057A0/en
Application filed by Zelira Therapeutics Operations Pty Ltd filed Critical Zelira Therapeutics Operations Pty Ltd
Publication of CL2023001298A1 publication Critical patent/CL2023001298A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una composición que comprende uno o más cannabinoides, un potenciador de la permeabilidad y un polímero de alginato, en la que el cannabinoide o los cannabinoides y el potenciador de la permeabilidad están encapsulados. Dichas composiciones pueden ser útiles en el tratamiento de trastornos neurodegenerativos, en los que se requiere la administración de un cannabinoide al cerebro.
CL2023001298A 2020-11-06 2023-05-04 Tecnología de encapsulación de cannabinoides CL2023001298A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2020904057A AU2020904057A0 (en) 2020-11-06 Cannabinoid Encapsulation Technology

Publications (1)

Publication Number Publication Date
CL2023001298A1 true CL2023001298A1 (es) 2023-10-13

Family

ID=81458267

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001298A CL2023001298A1 (es) 2020-11-06 2023-05-04 Tecnología de encapsulación de cannabinoides

Country Status (13)

Country Link
US (1) US20230404944A1 (es)
EP (1) EP4240347A1 (es)
JP (1) JP2023552004A (es)
KR (1) KR20230128451A (es)
CN (1) CN116685312A (es)
AU (1) AU2021376539A1 (es)
CA (1) CA3204196A1 (es)
CL (1) CL2023001298A1 (es)
CO (1) CO2023007094A2 (es)
IL (1) IL303034A (es)
MX (1) MX2023005339A (es)
PE (1) PE20240682A1 (es)
WO (1) WO2022094671A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783450A (en) * 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US8808734B2 (en) * 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
CN105916492A (zh) * 2013-10-31 2016-08-31 全谱实验室有限公司 萜烯和大麻素制剂
JP2018505912A (ja) * 2014-12-12 2018-03-01 オーハイ エナジェティクス ピービーシー マイクロカプセル化カンナビノイド組成物
EP3644986A4 (en) * 2017-05-01 2021-01-06 MJ Wooly Corporation METHODOLOGY AND FORMULATION FOR CREATING A POWDER FROM AN ENCAPSULATED CANNABIS-BASED COMPONENT INCORPORATED IN A POLYMERIC MATRIX
US20220378699A1 (en) * 2019-10-28 2022-12-01 Israel Plastics and Rubber Center Ltd. Self-emulsifying cannabis extract

Also Published As

Publication number Publication date
EP4240347A1 (en) 2023-09-13
KR20230128451A (ko) 2023-09-05
IL303034A (en) 2023-07-01
PE20240682A1 (es) 2024-04-10
MX2023005339A (es) 2023-05-22
US20230404944A1 (en) 2023-12-21
CO2023007094A2 (es) 2023-10-09
CA3204196A1 (en) 2022-05-12
CN116685312A (zh) 2023-09-01
AU2021376539A1 (en) 2023-06-15
WO2022094671A1 (en) 2022-05-12
JP2023552004A (ja) 2023-12-13

Similar Documents

Publication Publication Date Title
EA201990030A1 (ru) Способы и композиции для снижения окислительного стресса
CY1123351T1 (el) Χρηση του κανναβιδιολικου οξεος στη θεραπεια της επιληψιας
MX2019000427A (es) Formas de dosificacion oral de cannabinoide de alta concentracion.
CL2020003368A1 (es) Composicion y metodo para tratar el dolor
MX2020007784A (es) Uso de cannabinoides en el tratamiento de la epilepsia.
UY38476A (es) Inhibidores de arg1 y/o arg2
MD3452448T2 (ro) Modulatori ai răspunsului integrat la stres
AR072003A1 (es) Efectos antitumorales de combinaciones cannabinoides
CO2019001043A2 (es) Composición de cannabis
BR112016006898A2 (pt) composições de fragmentos de proteína de seda e seus artigos manufaturados
BR112019018088A2 (pt) Composições propositadamente selecionadas que compreendem canabinoides purificados e/ou terpenos purificados
MX2020001525A (es) Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
DK2053929T3 (da) Resin-indkapslet højintensivt sødemiddel
MY152710A (en) Oral compositions containing extracts of garcinia mangostana l. and related methods
DE602007011766D1 (de) Zusammensetzung mit nicht-psychotropen Cannabinoiden zur Behandlung von Entzündungserkrankungen
PA8719401A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CL2020003374A1 (es) Composicion y metodo de cannabinoides para tratar el tept y/o la ansiedad
CO2020000111A2 (es) Composición de gránulos veterinarios que contiene extracto de cáñamo
FR3061856B1 (fr) Utilisations therapeutiques d'une poudre d'insectes
CO2021001057A2 (es) Composición y método para el ahorro de opioides
EA202092730A1 (ru) Противомикробная композиция на основе полифенолов и полисахаридов, способ ее получения и применение
GB2564459A8 (en) Use of cannabinoids in the treatment of a neurodegenerative disease or disorder
CL2023001298A1 (es) Tecnología de encapsulación de cannabinoides
ATE490273T1 (de) Gelatinkapseln
HUP0402628A2 (hu) Helyettesített benzopiránok, mint szelektív ösztrogénreceptor-béta agonisták